We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


26 Oct 2017 By Robert Cyran

Some $30 bln of Celgene’s market value has vaporized in recent days after it admitted it bought a dud asset and axed $1-2 bln of revenue from its long-term forecast. The combination of an insufficiently productive pipeline and unreliable M&A is familiar to big drugmakers.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)